Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Work In Process (2021 - 2024)

Apellis Pharmaceuticals filings provide 4 years of Work In Process readings, the most recent being $106.2 million for Q1 2024.

  • For the quarter ending Q1 2024, Work In Process rose 119.02% year-over-year to $106.2 million, compared with a TTM value of $106.2 million through Mar 2024, up 119.02%, and an annual FY2023 reading of $82.9 million, up 53.28% over the prior year.
  • Work In Process hit $106.2 million in Q1 2024 for Apellis Pharmaceuticals, up from $82.9 million in the prior quarter.
  • The five-year high for Work In Process was $106.2 million in Q1 2024, with the low at $10.1 million in Q4 2021.
  • Median Work In Process over the past 4 years was $48.4 million (2023), compared with a mean of $48.1 million.
  • The sharpest move saw Work In Process skyrocketed 437.89% in 2022, then skyrocketed 53.28% in 2023.
  • Year by year, Work In Process stood at $10.1 million in 2021, then soared by 437.89% to $54.1 million in 2022, then soared by 53.28% to $82.9 million in 2023, then grew by 28.02% to $106.2 million in 2024.
  • According to Business Quant data, Work In Process over the past three periods came in at $106.2 million, $82.9 million, and $52.1 million for Q1 2024, Q4 2023, and Q3 2023 respectively.